Prof. PeptideProf. Peptide

GABA

Growth Hormone Support

Last reviewed: May 26, 2026

Also Known As: Gamma-aminobutyric acid, PharmaGABA (fermented form), GABA HCl

Supplement Class: Inhibitory neurotransmitter / peripheral GABA-A receptor agonist / somatostatin inhibitor (GH protocol)

Evidence Tier: Mixed — Moderate for low-dose PharmaGABA sleep and stress (Yamatsu et al. 2016's polysomnography trial, Abdou et al. 2006, Kanehira et al. 2011); Moderate but contested for the high-dose GH protocol (Powers et al. 2008's dramatic n=11 finding, limited independent replication at the same magnitude); the mechanism debate over blood-brain barrier penetration remains active and unresolved.

Buy on Amazon

As an Amazon Associate, Prof. Peptide earns from qualifying purchases.

What is GABA?

GABA (gamma-aminobutyric acid) is the primary inhibitory neurotransmitter in the central nervous system, responsible for reducing neural excitability and supporting calm, relaxation, and sleep. Endogenous GABA is synthesized in the brain from glutamate via glutamic acid decarboxylase and binds GABA-A and GABA-B receptors throughout the nervous system — the same receptor system targeted by benzodiazepines, Z-drugs, and alcohol, though supplemental GABA is discussed as producing a much milder effect without dependence risk. The central mechanism debate is whether oral GABA can meaningfully cross the blood-brain barrier — traditional pharmacology says no, while more recent evidence suggests peripheral GABA receptors in the gut/vagus, possible BBB penetration at high doses, and general circulating GABA modulation may produce the documented clinical effects. Sleep evidence is moderate and polysomnography-confirmed at low doses (Yamatsu et al. 2016's PharmaGABA 100 mg/day trial reducing sleep onset latency and increasing deep sleep). Stress reduction is moderate (Abdou et al. 2006's chromogranin A biomarker confirmation; Kanehira et al. 2011's EEG confirmation). The most striking finding reviewed is Powers et al. 2008 — 3 g oral GABA elevated immunoreactive GH by roughly 400% at rest in resistance-trained men, with larger increases following exercise, though the small sample (n=11), biomarker outcome, and limited independent replication temper this finding. The PharmaGABA form (Lactobacillus hilgardii fermentation) has stronger clinical evidence than synthetic GABA for sleep/anxiety applications. GABA is discussed alongside sleep peptides like DSIP and Selank and with GH-axis peptides like CJC-1295 and Ipamorelin for users targeting comprehensive GH support.

Reported benefits:

  • Reduced sleep onset latency and improved deep sleep (Yamatsu et al. 2016's polysomnography study at 100 mg PharmaGABA)
  • Reduced subjective stress and salivary stress biomarkers (Abdou et al. 2006 at 100 mg)
  • EEG-confirmed relaxation response (Kanehira et al. 2011)
  • Significant growth hormone elevation at 3 g (Powers et al. 2008, roughly 400% immunoreactive GH increase)
  • Modest blood-pressure reduction in pre-hypertensive populations
  • Modest anxiolytic effects (smaller than benzodiazepines or even L-theanine)
  • Immune modulation via peripheral GABA-A receptors on T lymphocytes (Tian et al. 2004)

Common dose: 100–300 mg PharmaGABA pre-bed for sleep/anxiety (the Yamatsu et al. 2016 trial range); 3–5 g synthetic GABA on an empty stomach pre-bed or post-workout for the GH protocol (the Powers et al. 2008 dose). Tingling/flushing is common at the higher synthetic-GABA doses — reported as harmless but uncomfortable.

Drug interaction caveat: Combining with alcohol, benzodiazepines (Xanax, Valium), Z-drugs (Ambien), or other CNS depressants is generally avoided given additive sedation risk. Avoiding driving after high doses until tolerability is known is standard guidance.

On this page
  1. 1.How does GABA work?
  2. 2.What does the evidence say GABA does?
  3. 3.How is GABA dosed?
  4. 4.How GABA is taken
  5. 5.What does GABA stack with?
  6. 6.Side effects and interactions
  7. 7.What isn't established about GABA
  8. 8.Product-quality considerations
  9. 9.GABA FAQ
  10. 10.References
  11. 11.Published Studies

How does GABA work?

GABA is the primary inhibitory neurotransmitter in the central nervous system. Endogenous GABA is synthesized in the brain from glutamate via glutamic acid decarboxylase and binds GABA-A and GABA-B receptors to reduce neural excitability. The supplement mechanism is more complicated: the blood-brain barrier traditionally prevents oral GABA from directly accessing CNS receptors, so the documented clinical effects are discussed as likely operating through peripheral GABA receptors, vagal afferent signaling, and (debatedly) some direct CNS penetration at very high doses.

  1. Endogenous GABA biology. GABA is the brain's major inhibitory neurotransmitter, reported to account for roughly 30% of CNS synaptic activity. It opens chloride channels at GABA-A receptors, hyperpolarizing post-synaptic neurons and reducing their firing — the same receptor system benzodiazepines and Z-drugs modulate, though supplemental GABA is discussed as acting on the same receptors with a much milder effect and without dependence risk.
  2. Blood-brain barrier debate. Traditional pharmacology held that GABA's polar structure prevents meaningful BBB penetration, implying oral GABA should not produce CNS effects. More recent evidence challenges this: animal studies report some BBB penetration of GABA at higher doses, and the BBB has GABA transporters that may allow regulated transport. The mechanism debate remains unresolved in the sources reviewed.
  3. Peripheral GABA receptors and gut-brain axis. GABA-A receptors are expressed in the enteric nervous system, vagal afferents, and immune cells. Oral GABA may activate these peripheral receptors and transmit inhibitory signals to the brain indirectly via the gut-brain axis, providing a mechanism for documented CNS effects despite limited direct BBB penetration. Tian et al. 2004 documented immune-cell GABA-A receptor expression supporting this peripheral mechanism arm.
  4. Growth hormone stimulation via somatostatin inhibition. Powers et al. 2008 reports dramatic GH elevation after 3 g oral GABA. The proposed mechanism is GABA-mediated inhibition of somatostatin (the hormone that suppresses GH release), relieving the somatostatin brake on pituitary GH secretion — a plausible mechanism whose magnitude needs independent replication.
  5. Sleep architecture effects. Yamatsu et al. 2016 reports polysomnographic improvements (reduced sleep onset latency, increased deep sleep) with low-dose PharmaGABA, supporting that the sleep effects are not purely a subjective placebo response.
  6. PharmaGABA vs synthetic GABA. PharmaGABA is produced by Lactobacillus hilgardii fermentation; synthetic GABA is chemically produced. The molecule is identical; the clinical evidence base favors PharmaGABA — possibly due to co-occurring fermentation metabolites that enhance peripheral GABA receptor effects, or possibly reflecting publication patterns.

What does the evidence say GABA does?

GABA has a moderate but contested evidence base reviewed for this site — mechanistically debated due to the BBB question, but with multiple human RCTs reporting measurable outcomes (sleep, stress markers, GH release). Effect sizes are modest in absolute terms but consistent across the trial base, particularly for PharmaGABA at low doses.

  1. Sleep onset and quality (Moderate, polysomnography-confirmed). Yamatsu et al. 2016 reports reduced sleep-onset latency and increased deep sleep duration on polysomnography with 100 mg/day PharmaGABA, with subsequent trials replicating the subjective sleep improvement.
  2. Stress reduction (Moderate). Abdou et al. 2006 reports reduced salivary chromogranin A (a stress biomarker) and subjective stress with 100 mg GABA; Kanehira et al. 2011 adds EEG biomarker confirmation. The effect is described as real but modest, not benzodiazepine-class.
  3. Growth hormone release (Moderate). Powers et al. 2008 reports dramatic GH elevation (roughly 400% at rest, roughly 200% post-exercise) with 3 g oral GABA. A small sample (n=11), biomarker-only outcome, and limited independent replication at the same magnitude temper this finding, though it is mechanistically plausible via somatostatin inhibition.
  4. Anxiolytic effects (Modest). Several trials report modest anxiety reduction with GABA supplementation, with effects smaller than benzodiazepines or even L-theanine for similar contexts.
  5. Blood pressure reduction (Modest). Some trials in pre-hypertensive populations report modest BP reductions with PharmaGABA, with a mechanism likely involving peripheral vasodilation and stress-response modulation.
  6. Immune modulation (Mechanistic). Tian et al. 2004 documented T-lymphocyte GABA-A receptor expression supporting peripheral immune modulation, though the clinical relevance in healthy users is modest.
  7. Body composition (Speculative-Emerging). The Powers et al. 2008 GH elevation has been hypothesized to translate to body composition benefits, but direct trials measuring lean mass, fat mass, or IGF-1 outcomes from chronic GABA supplementation are sparse in the sources reviewed — the GH-to-body-composition causal chain is not directly demonstrated.
  8. Healthy young-adult cognitive enhancement (Weak). GABA is not discussed as a cognitive enhancer in the conventional nootropic sense; relaxation effects may indirectly support cognitive performance via stress reduction, but standalone cognitive trials do not show a meaningful effect.

How is GABA dosed?

GABA dosing depends on goal and form. For sleep and stress (PharmaGABA): 100–300 mg pre-bed or as needed. For growth hormone stimulation (synthetic GABA): 3–5 g on an empty stomach, pre-bed or post-workout. The two protocols have different evidence bases and different practical considerations, since high-dose synthetic GABA commonly causes flushing/tingling.

Prof. Peptide reports what trials established and what research communities practice, labelled separately. Neither is a recommendation.

  1. Sleep / stress / anxiety (PharmaGABA). 100–300 mg pre-bed or as needed during stress. The Yamatsu et al. 2016 polysomnography trial used 100 mg/day; subsequent trials extend to 200 mg.
  2. Growth hormone protocol (synthetic GABA). 3–5 g on an empty stomach, pre-bed or 30–60 minutes post-workout — the Powers et al. 2008 trial protocol (3 g), with tingling/flushing to be expected at this dose.
  3. Acute anxiety / pre-stressor. 100–200 mg PharmaGABA 30–60 minutes before known anxiogenic events, with a mild effect compared to benzodiazepines.
  4. Chronic daily anxiolytic baseline. 100–200 mg PharmaGABA once or twice daily, reported as safe for chronic use with no tolerance documented at this dose.
  5. Upper bound. Doses above 5 g/day rarely add reported benefit and substantially increase tingling/flushing/breathing-pattern changes; no serious toxicity is documented, but tolerability suffers.

Reported timeline: PharmaGABA effects emerge within 30–60 minutes (acute use) or 1–2 weeks (chronic sleep protocol). Synthetic GABA's GH peak is within 60–90 minutes post-dose. Avoiding driving or operating machinery after high doses until tolerability is known is standard guidance.

Label math. "GABA 750 mg per serving" usually means synthetic GABA. "PharmaGABA 100 mg" means naturally fermented GABA, generally at a smaller dose but with stronger evidence for sleep/anxiety. Reading for the form explicitly is the relevant check, since the two carry different evidence bases.

How GABA is taken

GABA is taken orally as capsules, tablets, sublingual tablets (faster onset for some users), or powder. The practical considerations reported are form choice (PharmaGABA vs synthetic), goal-dependent dosing, and the flushing/tingling side effect at high doses.

AspectReported
FrequencyAs-needed for acute stress; once nightly for the sleep protocol; pre-bed or post-workout for the GH protocol; not typically used multiple times daily.
Best time of dayEvening (pre-bed) for sleep and GH protocols; 30–60 minutes before a known stressor for acute anxiety use.
FoodAn empty stomach is preferred for the GH protocol (Powers et al. 2008 used fasted dosing). For sleep/anxiety use, either works; food may modestly slow onset.
FormPharmaGABA (Lactobacillus hilgardii fermentation, naturally derived) carries the stronger clinical evidence for low-dose sleep/anxiety; synthetic GABA is used at higher doses for the GH protocol. Sublingual tablets may offer faster onset for some users.
Standardization markerA label reading "PharmaGABA" (the branded fermented form) is the marker for the trial-validated clinical-evidence form. For synthetic GABA, 99%+ purity with third-party testing is the relevant check; "GABA blends" that obscure actual mg per serving are generally avoided.
CyclingNo cycling is reported as pharmacologically required, with no tolerance development documented at clinical doses. For the GH protocol, some users pulse around training blocks rather than dosing continuously.

What does GABA stack with?

GABA is discussed alongside the broader sleep and stress modulation toolkit and the GH-axis support stack. The inhibitory neurotransmitter mechanism is reported as complementary to peptide-level sleep architecture interventions and Russian-origin sleep peptides.

With peptides

GABA is discussed alongside the Russian-origin sleep and cognitive peptide cluster. DSIP (delta sleep-inducing peptide) is reported to operate directly on slow-wave sleep architecture. Selank (a tuftsin analog) is reported to provide anxiolytic effects via GABA-A receptor sensitivity modulation — the same broad system as supplemental GABA but at a different mechanistic layer. No known negative interaction is documented in the sources reviewed for this page. Additionally, for GH-axis protocols, CJC-1295 and Ipamorelin directly stimulate pituitary GH release; GABA's somatostatin-inhibition arm (Powers et al. 2008) overlaps mechanism layers with these peptides, a combination discussed as compatible but worth monitoring for total GH-stimulation load.

With supplements

  1. Magnesium glycinate — a GABA-A positive allosteric modulator, discussed as pairing cleanly with supplemental GABA via complementary receptor-level effects.
  2. L-theanine — alpha-wave induction plus GABAergic enhancement via a different mechanism layer.
  3. Glycine — body-temperature regulation for sleep onset plus inhibitory neurotransmission via a different sleep mechanism.
  4. Apigenin — a direct GABA-A positive allosteric modulator, a complementary receptor-modulation arm to supplemental GABA substrate.
  5. Ashwagandha — adaptogenic cortisol-blunting plus emerging GH-axis effects, a common GH-stack co-occupant.
  6. ZMA — magnesium, zinc, and B6 for sleep architecture plus mineral repletion, a standard GH-stack pre-bed pairing.
  7. L-arginine — a nitric oxide precursor with modest GH-secretagogue effects at high doses.

With lifestyle factors

  1. Pre-bed timing for sleep. 30–60 minutes before target bedtime to align with the inhibitory-neurotransmission window.
  2. Post-workout GH protocol. 3 g synthetic GABA on an empty stomach 30–60 minutes after training follows the Powers et al. 2008 protocol; pairing with resistance training is discussed for a synergistic GH response.
  3. Pre-stressor timing for acute anxiety. 100–200 mg PharmaGABA 30–60 minutes before known anxiogenic events.
  4. Avoiding alcohol or sedatives. Given additive CNS depression risk, separating by 6+ hours is a common conservative rule.
  5. Driving after high doses. Avoiding driving until tolerability is known is standard guidance, since tingling, breathing-pattern changes, and mild sedation can affect motor function.

Side effects and interactions

GABA has a generally favorable safety profile in the sources reviewed. The main considerations reported are the dose-dependent tingling/flushing reaction, additive sedation with other CNS depressants, and breathing-pattern changes at high doses.

Common (mostly transient)

  1. Tingling / flushing — common at higher doses (1+ g synthetic GABA), particularly the GH protocol at 3 g; harmless and transient (resolving within 15–30 min), likely reflecting peripheral GABA receptor activation in skin and vasculature.
  2. Drowsiness — intentional for sleep applications, undesirable if dosed during the day; dose reduction is a common mitigation.
  3. Changes in breathing pattern — a shortness-of-breath sensation or unusual breathing rhythm at high doses, with the mechanism not fully characterized but generally described as benign and transient.
  4. Mild GI discomfort — occasional, usually at higher doses.
  5. No documented serious adverse events at standard supplemental doses across the human RCT base reviewed.

Less common (watch-list)

  1. Mood changes — rare reports of depression worsening, generally anecdotal.
  2. Pregnancy and breastfeeding — insufficient safety data; avoidance of supplemental GABA is standard guidance, though dietary GABA from fermented foods is generally considered fine.
  3. Driving / motor function effects at high doses — avoiding driving after first using high doses until tolerability is known is standard guidance.

Drug and supplement interactions

  1. Alcohol. Additive CNS depression is reported; avoiding the combination and separating by 6+ hours is standard guidance.
  2. Benzodiazepines (Xanax, Valium, Ativan, Klonopin). The same receptor system is involved; additive CNS depression is possible, so clinician coordination is standard guidance.
  3. Z-drugs (Ambien, Lunesta, Sonata). A similar mechanism class to benzodiazepines; additive sedation is reported, so combining is generally avoided.
  4. Antihistamines (sedating types — diphenhydramine, doxylamine). Additive sedation is reported; a modest risk generally tolerated but worth monitoring.
  5. Antihypertensive medications. A modest additive BP-lowering effect is reported; monitoring during titration is standard guidance.
  6. Other anxiolytic supplements (L-theanine, magnesium, apigenin) — generally compatible; watching total inhibitory tone is reasonable if stacking multiple GABAergic agents aggressively.
  7. GH secretagogue peptides (CJC-1295, Ipamorelin, Sermorelin) — a compatible mechanism, with GABA's somatostatin-inhibition arm discussed as complementary to direct GH stimulation.

What isn't established about GABA

GABA has a moderate but contested evidence base reviewed for this site — the BBB question is central, and several other open questions affect how confidently the supplement can be recommended.

Blood-brain barrier penetration debate. Traditional pharmacology holds that oral GABA cannot meaningfully cross the BBB, yet documented clinical effects (sleep, stress, GH) suggest some mechanism is operating. Whether it is peripheral GABA receptors via vagal afferents, the gut-brain axis, partial BBB penetration at high doses, or some combination remains unresolved in the sources reviewed.

Powers et al. 2008 GH magnitude replication. The roughly 400% immunoreactive GH increase is striking but from a small sample (n=11) and has not been replicated at the same magnitude across independent labs. Whether the GH effect produces meaningful body composition or recovery outcomes is not directly demonstrated in the sources reviewed.

PharmaGABA vs synthetic GABA outcome equivalence. PharmaGABA has more positive clinical-evidence sleep/anxiety trials; synthetic GABA has less. Whether this reflects a genuine bioactivity difference or publication patterns is unresolved.

Long-term high-dose safety. Most trial data reviewed extends to weeks at low-dose PharmaGABA (100–300 mg). Multi-year use at GH-protocol doses (3+ g/day) is not directly RCT-characterized in the sources reviewed.

Anxiety populations beyond mild stress. Most positive trials reviewed are in healthy adults under acute stress or mild anxiety. Whether GABA produces meaningful benefit in clinical anxiety disorders (generalized anxiety, panic disorder, PTSD) is mechanistically reasonable but not directly demonstrated.

Body composition from chronic GH stimulation. Powers et al. 2008 documented acute GH elevation but did not measure body composition outcomes; whether chronic GABA supplementation produces meaningful body-composition benefits via the GH pathway is plausible but not directly trial-confirmed.

Breathing-pattern changes mechanism. The shortness-of-breath sensation at high doses is consistently reported, but the mechanism is not fully characterized in the sources reviewed.

Product-quality considerations

GABA is widely available over-the-counter. PharmaGABA branded products have stronger clinical evidence; generic synthetic GABA is less expensive and used in the GH protocol.

Quality markers reported in the category

  • PharmaGABA — the naturally fermented form with the strongest sleep/anxiety clinical evidence, typically dosed at 100–200 mg.
  • Synthetic GABA 99%+ purity — for the higher-dose GH protocol, where dose magnitude matters more than form.
  • Form explicitly disclosed — reading for "PharmaGABA" or "synthetic GABA" rather than "GABA" without form specification.
  • Third-party testing — USP, NSF, or ConsumerLab certification signals independent verification.
  • cGMP-certified manufacturing facility.
  • No proprietary sleep / anxiety blends that obscure the actual GABA dose alongside other ingredients.
  • Sublingual format if faster onset is desired — held under the tongue for absorption.
Buy on Amazon

As an Amazon Associate, Prof. Peptide earns from qualifying purchases.

GABA FAQ

Does GABA cross the blood-brain barrier?

This is debated. The traditional pharmacology view holds that GABA's polar molecular structure prevents meaningful blood-brain barrier penetration, meaning oral GABA could not directly act on CNS GABA receptors. More recent evidence suggests several alternative mechanisms: peripheral GABA receptors in the enteric nervous system communicating via vagal afferents to the brain, possible direct CNS penetration at very high doses, and effects on circulating GABA levels that may indirectly modulate CNS activity. The mechanism is genuinely unresolved in the literature reviewed, but multiple RCTs report measurable outcomes (sleep, anxiety, stress markers, GH release). PharmaGABA (the naturally fermented form) has stronger evidence for these effects than synthetic GABA in some research.

How do PharmaGABA and synthetic GABA compare?

PharmaGABA is produced by Lactobacillus hilgardii fermentation, the same bacterial fermentation process used in traditional Japanese fermented foods; synthetic GABA is chemically synthesized. The molecule itself is identical in both forms. The difference reported is in trial evidence: PharmaGABA has more positive human trials for sleep, anxiety, and stress effects, while synthetic GABA has thinner clinical evidence. This may reflect bioavailability differences from co-occurring metabolites in the fermented form, or it may reflect publication patterns. PharmaGABA is generally used for clinical-evidence-backed use; synthetic GABA at higher doses (3+ g) for the growth hormone protocol, where the dose magnitude matters more than form.

Is the 400% growth hormone increase from GABA a real finding?

Yes, within the specific trial. Powers et al. 2008 reports immunoreactive GH increasing roughly 400% and immunofunctional GH roughly 200% after 3 g oral GABA in healthy resistance-trained men at rest, with larger increases following exercise. The proposed mechanism involves GABA's modulation of somatostatin (the hormone that suppresses GH release). Important caveats discussed: the sample size was small (n=11); immunoreactive and immunofunctional GH are biomarker measurements, not necessarily equivalent to biologically active GH producing downstream effects on body composition, recovery, or IGF-1; and the dramatic percentage increase is from a low baseline, with absolute GH levels still in physiological range. The finding is striking and mechanistically plausible but has not been replicated at the same magnitude across independent labs.

What dose of GABA is discussed for different goals?

The dose depends on goal. For sleep and relaxation: 100–300 mg PharmaGABA taken 30–60 minutes before bed. For growth hormone stimulation: 3–5 g synthetic GABA on an empty stomach, pre-bed or post-workout (the Powers et al. 2008 protocol). For acute anxiety: 100–200 mg PharmaGABA as needed. Higher doses (3+ g) may cause a tingling sensation and changes in breathing pattern — common side effects, generally described as benign but worth being aware of, particularly before driving or operating machinery until tolerability is known.

Does GABA stack with DSIP or other sleep peptides?

The combination is discussed as mechanistically natural for users layering sleep interventions across mechanisms. DSIP (delta sleep-inducing peptide) is reported to operate directly on slow-wave sleep architecture — a peptide-level intervention on sleep depth. Selank (a tuftsin analog) is reported to provide anxiolytic effects via GABA modulation — the same broad mechanism as supplemental GABA but at a different layer, since Selank is discussed as modulating GABA-A receptor sensitivity rather than supplying GABA substrate. No known negative interaction is documented in the sources reviewed for this page. For users on CJC-1295 / Ipamorelin GH-axis protocols — GABA's GH-release effect (Powers et al. 2008) overlaps mechanism layers; this is not reported as a problem, but watching for over-stimulation of GH when combining high-dose GABA with GH secretagogue peptides is a reasonable precaution.

Does GABA meaningfully help with sleep?

The evidence suggests a modest real effect beyond placebo, particularly for PharmaGABA. Multiple Japanese trials report reduced sleep-onset latency, improved sleep quality, and reduced stress markers with 100–300 mg PharmaGABA pre-bed. Effect sizes are described as modest — GABA is not a benzodiazepine-class sedative — but consistent across the trial base reviewed. Whether the mechanism is direct CNS GABA receptor activation, peripheral GABA receptors via vagal afferents, or general circulating GABA modulation remains debated. Evaluation at the 2-week mark, rather than after a single dose, is a reasonable approach before concluding it is not working.

Why does GABA cause a tingling sensation on the skin?

The flushing/tingling reaction is a real and commonly reported effect, particularly at higher doses (1+ g). The mechanism is not fully characterized but likely involves peripheral GABA receptors in the skin and vasculature producing vasodilation. The sensation is reported as harmless and transient (typically resolving within 15–30 minutes), though uncomfortable for some users. Lowering the dose, or switching to PharmaGABA at lower doses (100–200 mg), is a common mitigation, since the high-dose synthetic GABA used for the GH protocol is what most commonly produces the flushing reaction.

Is combining GABA with alcohol or sedatives discussed as safe?

This is generally not recommended. GABA's mechanism overlaps with benzodiazepines (which modulate GABA-A receptors), Z-drugs (Ambien and similar), and alcohol — all CNS depressants acting on or near the GABAergic system. Combining supplemental GABA with these can produce additive sedation, respiratory depression at high doses, and unpredictable interactions. Avoiding GABA on days involving alcohol or prescription sedatives is a conservative rule of thumb, and clinician coordination is standard guidance for users on chronic benzodiazepine therapy or similar before adding GABA.

References

  1. Powers ME, Yarrow JF, McCoy SC, Borst SE. Growth hormone isoform responses to GABA ingestion at rest and after exercise. Med Sci Sports Exerc. 2008;40(1):104-110. https://pubmed.ncbi.nlm.nih.gov/18091016/
  2. Abdou AM, Higashiguchi S, Horie K, Kim M, Hatta H, Yokogoshi H. Relaxation and immunity enhancement effects of gamma-aminobutyric acid (GABA) administration in humans. Biofactors. 2006;26(3):201-208. https://pubmed.ncbi.nlm.nih.gov/16971751/
  3. Tian J, Lu Y, Zhang H, Chau CH, Dang HN, Kaufman DL. Gamma-aminobutyric acid inhibits T cell autoimmunity and the development of inflammatory responses in a mouse type 1 diabetes model. J Immunol. 2004;173(8):5298-5304. https://pubmed.ncbi.nlm.nih.gov/15470076/
  4. Yamatsu A, Yamashita Y, Pandharipande T, Maru I, Kim M. Effect of oral γ-aminobutyric acid (GABA) administration on sleep and its absorption in humans. Food Sci Biotechnol. 2016;25(2):547-551. https://link.springer.com/article/10.1007/s10068-016-0076-9
  5. Kanehira T, Nakamura Y, Nakamura K, et al. Relieving occupational fatigue by consumption of a beverage containing γ-amino butyric acid. J Nutr Sci Vitaminol (Tokyo). 2011;57(1):9-15. https://pubmed.ncbi.nlm.nih.gov/21512285/
  6. Boonstra E, de Kleijn R, Colzato LS, Alkemade A, Forstmann BU, Nieuwenhuis S. Neurotransmitters as food supplements: the effects of GABA on brain and behavior. Front Psychol. 2015;6:1520. https://pubmed.ncbi.nlm.nih.gov/26500584/

Published Studies

Plain-English summaries of the peer-reviewed studies behind the claims above. Click any title to read the source paper.

Medicine & Science in Sports & Exercise · 2008Paywalled
Growth Hormone Isoform Responses to GABA Ingestion at Rest and After Exercise →

Powers ME, Yarrow JF, McCoy SC, Borst SE

A randomized double-blind placebo-controlled crossover trial of 3 g oral GABA in 11 healthy resistance-trained men at rest and after exercise. Reports GABA significantly elevated immunoreactive GH by roughly 400% at rest and roughly 200% post-exercise versus placebo, and immunofunctional GH by roughly 200% at rest and roughly 175% post-exercise — the foundational evidence for GABA's growth hormone effect. Caveats include a small sample (n=11), a biomarker-based outcome (not body composition or IGF-1), and limited independent replication at the same magnitude.

BioFactors · 2006Paywalled
Relaxation and Immunity Enhancement Effects of Gamma-Aminobutyric Acid (GABA) Administration in Humans →

Abdou AM, Higashiguchi S, Horie K, Kim M, Hatta H, Yokogoshi H

A randomized placebo-controlled trial of 100 mg GABA in 13 stressed adults during arithmetic-task stress. Reports GABA significantly reduced subjective stress (chromogranin A salivary biomarker) and modulated immune parameters (IgA response) versus placebo — foundational evidence for GABA's stress-reduction effect at a low oral dose.

Journal of Immunology · 2004Open Access
Gamma-Aminobutyric Acid Inhibits T Cell Autoimmunity and the Development of Inflammatory Responses in a Mouse Type 1 Diabetes Model →

Tian J, Lu Y, Zhang H, Chau CH, Dang HN, Kaufman DL

A mechanistic study documenting GABA's peripheral effects on T lymphocyte function via GABA-A receptors expressed on immune cells in a mouse model. Supports the peripheral GABA receptor mechanism arm discussed for oral GABA supplementation.

Food Science and Biotechnology · 2016Open Access
Effect of Oral γ-Aminobutyric Acid (GABA) Administration on Sleep and Its Absorption in Humans →

Yamatsu A, Yamashita Y, Pandharipande T, Maru I, Kim M

A placebo-controlled trial of 100 mg/day PharmaGABA in healthy adults with subjective sleep complaints. Reports PharmaGABA significantly reduced sleep-onset latency and increased deep sleep duration on polysomnography versus placebo — polysomnographic confirmation that the sleep effect is not purely subjective.

Journal of Nutritional Science and Vitaminology · 2011Open Access
Relieving Occupational Fatigue by Consumption of a Beverage Containing γ-Amino Butyric Acid →

Kanehira T, Nakamura Y, Nakamura K, et al.

A controlled trial assigning an arithmetic stress task (Uchida-Kraepelin Psychodiagnostic Test) to 30 adults consuming a GABA-containing beverage, measuring EEG and subjective stress responses. Reports GABA modulated alpha and beta wave activity consistent with reduced mental stress and increased relaxation versus placebo — EEG biomarker confirmation of GABA's stress-modulating effects.

SleepGrowth HormoneInhibitory NeurotransmitterPharmaGABABBB DebatePowers 2008

Related Supplements

MagnesiumL-TheanineGlycineApigeninAshwagandhaZMA

We may earn commissions from peptide vendor affiliate links.

Have a question about GABA? Send us an email